Physiology Optimized Versus Angio-guided PCI (AQVA-II)
Coronary Artery Disease, Percutaneous Coronary Intervention
About this trial
This is an interventional treatment trial for Coronary Artery Disease focused on measuring Percutaneous coronary intervention, Fractional Flow Reserve, Virtual PCI plan
Eligibility Criteria
Inclusion Criteria: Indication to PCI for either acute or chronic coronary syndrome Signed informed consent At least one of the following CHIP lesion characteristic: Long lesion (>28 mm); Tandem lesions; Severe calcifications; Severe tortuosity; True bifurcation lesions: involving a significant (> 50%) diameter stenosis both in the main vessel and side branch (i.e. MEDINA 1,1,1; 1,0,1; or 0,1,1) and with a relevant side branch, namely ≥2.00 mm; In-stent restenosis (ISR). Left main stem disease. Exclusion Criteria: Planned surgical revascularization Prior Coronary Artery Bypass Graft (CABG) Surgery Culprit lesion of STEMI or NSTEMI Revascularization of a chronic total occlusion Non-cardiovascular co-morbidity reducing life expectancy to < 1 year Any factor precluding 1-year follow-up
Sites / Locations
- University Hospital of Ferrara
- Santa Maria Goretti Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Experimental
Experimental
Angiography-guided PCI
Microcatheter-derived FFR
Angiography-derived FFR
Patients will receive PCI according to the interpretation of angiography findings by the Interventional Cardiologist.
Patients will receive PCI according to the plan derived from the interpretation of the FFR pullback obtained with microcatheter FFR performed by the Interventional Cardiologist before and after PCI.
Patients will receive PCI according to the plan derived from the interpretation of the FFR pullback obtained with angiography-derived FFR performed by the Interventional Cardiologist before PCI. The angiography-derived FFR can be repeated after PCI to check the results and eventually apply correcting maneuvers.